https://www.selleckchem.com/pr....oducts/tunicamycin.h
Rituximab is effective for maintaining remission in patients with complicated nephrotic syndrome, although a history of steroid-resistant nephrotic syndrome (SRNS) is a risk factor for early relapse. We investigated the efficacy of prophylactic rituximab treatment for maintaining remission after B cell recovery. Patients with complicated steroid-dependent or frequently relapsing nephrotic syndrome with history of SRNS who received a single dose of rituximab (375 mg/m ) and continued immunosuppressive agents were enrolled in this ret
Beğen
Yorum Yap
Paylaş
